Access requires that you are 21 years of age or older. Products are for laboratory and research use only — not for human or veterinary use, consumption, or clinical application.
Access requires that you are 21 years of age or older. Products are for laboratory and research use only — not for human or veterinary use, consumption, or clinical application.
Thymosin Alpha-1 reference material, supplied as a lyophilized powder in a sealed vial for in-vitro laboratory research and analytical method development. Each fill size is a separate SKU. Lot and COA records are shown when assigned.
This listing is a research chemical / reference material. No therapeutic, preventive, or diagnostic claims are made or implied. The storefront displays only approved analytical characterization data released through its public report records.
Thymosin Alpha-1 is a synthetic 28-amino-acid polypeptide of 28 amino acids. A peptide hormone produced naturally by the thymus. The synthetic version derives from thymosin fraction 5, a thymic extract first isolated in the 1970s.
Reported to activate Toll-like receptors, shift macrophage behaviour, enhance T-cell differentiation, and modulate cytokine signalling — described as acting across several pathways rather than one. Vectra makes no claim as to mechanism or effect.
Thymosin Alpha-1 holds approval in approximately 35 countries, though never in the United States, where it remains investigational. An approval in another jurisdiction is not an FDA approval.
Thymosin Alpha-1 reference material, supplied as a lyophilized powder in a sealed vial for in-vitro laboratory research and analytical method development. Each fill size is a separate SKU. Lot and COA records are shown when assigned.
This listing is a research chemical / reference material. No therapeutic, preventive, or diagnostic claims are made or implied. The storefront displays only approved analytical characterization data released through its public report records.
Thymosin Alpha-1 is a synthetic 28-amino-acid polypeptide of 28 amino acids. A peptide hormone produced naturally by the thymus. The synthetic version derives from thymosin fraction 5, a thymic extract first isolated in the 1970s.
Reported to activate Toll-like receptors, shift macrophage behaviour, enhance T-cell differentiation, and modulate cytokine signalling — described as acting across several pathways rather than one. Vectra makes no claim as to mechanism or effect.
Thymosin Alpha-1 holds approval in approximately 35 countries, though never in the United States, where it remains investigational. An approval in another jurisdiction is not an FDA approval.
Derived from thymosin fraction 5, first isolated in the 1970s. Approved in roughly 35 countries for hepatitis B and C, but never approved in the United States.
Studied in chronic viral infection, oncology, and immune ageing. Vectra supplies it as a reference material for in-vitro laboratory research and analytical method development only.
Our sources describe the evidence base as uneven by indication: genuine clinical data in specific infectious-disease contexts, and a growing but less settled body in oncology and ageing. No trial names, participant counts, designs or PMIDs are recorded.
No adverse-effect, toxicity, contraindication or interaction data is recorded in our sources.
Our sources carry no CAS number, formula, molecular weight, sequence, or storage data for Thymosin Alpha-1.
Approved in roughly 35 countries. Not approved in the United States. No therapeutic, preventive, or diagnostic claims are made or implied.
These are the specific, documented failure modes that lot-level third-party analysis addresses. A report reachable from the lot code printed on the vial — without asking the seller for it — is the only document that answers 'is this vial what the label says'. That is why every Vectra vial carries a QR code resolving to its own lot's published report.
Findings reported by commercial testing providers. Each names its source; none is registry- or peer-review-grade, so read them as a documented pattern rather than established prevalence.
Yes, and altered certificates have been reported in this market at material rates — see the testing findings above. Three properties make a report hard to fake:
Peptide identity data in the vendor market is often wrong in ways that are hard to see. Near-identical compounds get their CAS numbers, residue ranges, formulas and molecular weights swapped. A certificate can be internally consistent and still describe a different molecule than the label names. Most commercial peptide material ships as an acetate salt, not free base. The two forms have different measured masses, so a figure quoted against the wrong one will not reconcile. A report that does not state which form it assayed cannot be checked at all.
The standard our own reports are built to meet:
FDA has acted in this market between 2024 and 2026. Actions include a civil forfeiture over $1.7 million against a compounding operation, several rounds of warning letters to peptide vendors, and more than thirty letters in March 2026 concerning compounded GLP-1 products.
Buyers here increasingly compare document trail, not price.
Derived from thymosin fraction 5, first isolated in the 1970s. Approved in roughly 35 countries for hepatitis B and C, but never approved in the United States.
Studied in chronic viral infection, oncology, and immune ageing. Vectra supplies it as a reference material for in-vitro laboratory research and analytical method development only.
Our sources describe the evidence base as uneven by indication: genuine clinical data in specific infectious-disease contexts, and a growing but less settled body in oncology and ageing. No trial names, participant counts, designs or PMIDs are recorded.
No adverse-effect, toxicity, contraindication or interaction data is recorded in our sources.
Our sources carry no CAS number, formula, molecular weight, sequence, or storage data for Thymosin Alpha-1.
Approved in roughly 35 countries. Not approved in the United States. No therapeutic, preventive, or diagnostic claims are made or implied.
These are the specific, documented failure modes that lot-level third-party analysis addresses. A report reachable from the lot code printed on the vial — without asking the seller for it — is the only document that answers 'is this vial what the label says'. That is why every Vectra vial carries a QR code resolving to its own lot's published report.
Findings reported by commercial testing providers. Each names its source; none is registry- or peer-review-grade, so read them as a documented pattern rather than established prevalence.
Yes, and altered certificates have been reported in this market at material rates — see the testing findings above. Three properties make a report hard to fake:
Peptide identity data in the vendor market is often wrong in ways that are hard to see. Near-identical compounds get their CAS numbers, residue ranges, formulas and molecular weights swapped. A certificate can be internally consistent and still describe a different molecule than the label names. Most commercial peptide material ships as an acetate salt, not free base. The two forms have different measured masses, so a figure quoted against the wrong one will not reconcile. A report that does not state which form it assayed cannot be checked at all.
The standard our own reports are built to meet:
FDA has acted in this market between 2024 and 2026. Actions include a civil forfeiture over $1.7 million against a compounding operation, several rounds of warning letters to peptide vendors, and more than thirty letters in March 2026 concerning compounded GLP-1 products.
Buyers here increasingly compare document trail, not price.